AMORPHOUS FORM OF A THIOCOLCHICINE DERIVATIVE
20170022155 ยท 2017-01-26
Assignee
Inventors
- Walter Cabri (Milano, IT)
- Federico Peterlongo (Milano, IT)
- Daniele Ciceri (Milano, IT)
- Andrea Gambini (Milano, IT)
Cpc classification
C07C2603/34
CHEMISTRY; METALLURGY
International classification
Abstract
The present invention refers to an amorphous form of a thiocolchicine derivative, IDN 5404, to a process for producing it and to pharmaceutical compositions thereof. The amorphous form is characterised by the XRPD pattern, DSC profile and/or TG/DTA profile.
Claims
1. Amorphous compound of formula (I): ##STR00003## having the XRPD pattern shown in
2. The amorphous compound according to claim 1 having a DSC profile characterized by a glass transition with onset at 186.9 C. and endset at 194.5 C. recorded with a linear heating rate of 10 C./min.
3. The amorphous compound according to claim 1 having a TG/DTA profile characterized by an endothermic signal between 185.4 C. and 195.4 C. recorded with a linear heating rate of 10 C./min.
4. A process of preparing the amorphous compound of formula (I), as defined in claim 1, comprising the steps of: (a) dissolving the crude compound of formula (I) in DMSO; (b) removing the possible residual solvents coming from the synthetic process by heating the solution at 65 C. under vacuum; (c) precipitating the amorphous compound of formula (I) by adding drop wise the solution obtained in step b) to water at 20-25 C.
5. A pharmaceutical composition comprising the amorphous compound of formula (I) according to claim 1 and a pharmaceutically acceptable carrier and/diluent.
6. The pharmaceutical composition according to claim 5 for parenteral or oral administration.
7. The pharmaceutical composition according to claim 6 in form of injectable preparation.
8. The amorphous compound of formula (I) according to claim 1, for use in the treatment of solid tumors.
9. Method of treating solid tumors in subjects in need thereof, said method comprising administering an effective amount of the amorphous compound of formula (I) according to claim 1 to said subjects; and treating said subjects of said solid tumors.
Description
EXAMPLE 1
[0027] Crude IDN 5404 (1 kg) was dissolved in DMSO (8 L). The solution was heated at 65 C. and kept under vacuum for 2 hours in order to remove completely the solvents coming from the synthetic process. The solution was added drop wise to water (64 L) at 20-25 C. under stirring causing the precipitation of IDN 5404 as an amorphous solid. The resulting material was filtered and dried under vacuum to afford a quantitative yield of IDN 5404.
[0028] Characterisation of the Amorphous Form:
[0029] X-Ray Powder Diffraction (X-RPD)
[0030] X-RPD pattern was recorded on a Bruker D2-Phaser Diffractometer. The x-ray generator was operated at 30 kV and 10 mA, using the CuK line as the radiation source. The sample was packed on a suitable slit and the irradiated length was 10 mm. Data were collected between 2 and 50 deg 2-theta with a step size of 0.02 deg 2-theta and a counting time per step of 3 sec. The x-ray powder diffraction pattern of Amorphous (
[0031] Differential Scanning Calorimetry (DSC)
[0032] The analysis was performed using a Mettler DSC1 System. Heat flow was recorded from 30 to 300 C. with linear heating rate (10 C./min) under a 50 ml/min nitrogen flow. About 5 mg of powder was used for the measurement, in closed aluminium crucible (40 l volume) with a pinhole.
[0033] The DSC profile (
[0034] Fourier-Transform InfraRed Spectroscopy (FTIR)
[0035] The infrared spectrum was recorded in Attenuated Total Reflectance (ATR) mode using Fourier-Transform spectrometer Perkin Elmer Spectrum One, equipped with Specac ATR Golden Gate accessory. The spectrum is the result of the acquisition and transformation of 16 co-added scans in the 4000-550 cm.sup.1 spectral region at a re.
[0036] The FTIR-ATR spectrum is shown in
[0037] Thermogravimetry (TG) and Differential Thermal Analysis (DTA)
[0038] The analysis was performed using a Seiko TG/DTA7200 simultaneous system using open aluminum pans (40 l volume). The TG/DT signals were recorded from 30 to 300 C. with linear heating rate (10 C./min) under a 200 ml/min nitrogen flow. About 10 mg of powder was used for the measurement.
[0039] The TG/DTA profile (
EXAMPLE 2
Comparative
[0040] Crude IDN 5404 (500 mg) was purified by flash chromatography using as eluent AcOEt-Hexane 7:3. The fractions containing IDN 5404 were pooled and the solvent removed until dryness. IDN 5404 (310 mg) was obtained as a crystalline yellow solid with the following characteristics.
[0041] The product was analysed by GC to determine the residual organic solvents: AcOEt content is 11.1% (22 ppm of hexane) then it was assumed that the product could be a AcOEt solvate.
[0042] The TG/DTA and XRPD analysis were performed in the same conditions as example 1.
[0043] The TG/DTA profile of IDN5404 (AcOEt solvate) is represented in
[0044] Those peaks, attributable to release of crystallisation solvent followed by melting, are associated to a weight loss of 5.94% from 200 C. to 240 C.
[0045] The TG profile shows also a progressive weight loss of about 3.1% from 30 to 200 C., followed by a sharp weight loss in coincidence of the first endothermic peak.
[0046] The total loss of weight from 30 C. to 240 C. is 9.0%.
[0047] The XRPD diffractogram of IDN5404 (AcOEt solvate) is represented in
[0048] The diffractogram is characterized by intense diffraction peaks and sharp peak profile which indicates high crystallinity; the XRPD pattern shows distinctive reflections, expressed as 2-theta degrees values, at: 5.6-10.2-10.5-11.1-13.3-14.4-14.7-17.5-17.9-18.5-18.9-19.4-20.0-20.8-21.6-22.2-22.4-22.6-23.4-25.2-25.5-25.9-26.7-27.8-28.5-29.1-29.7-30.8-31.2-32.1.
EXAMPLE 3
Comparative
[0049] Crude IDN 5404 (500 mg) was purified by flash chromatography using as eluent CH2Cl2-EtOH 95:5. The fractions containing IDN 5404 were pooled and the solvent removed until dryness. IDN 5404 (315 mg) was obtained as a crystalline yellow solid with the following characteristics:
[0050] The product was analysed by GC to determine the residual organic solvents: EtOH content is 10.7% (269 ppm of CH2Cl2) then it was assumed that the product could be a EtOH solvate.
[0051] The TG/DTA and XRPD analysis were performed in the same conditions as example 1.
[0052] The TG/DTA profile of IDN5404 (EtOH solvate) is represented in
[0053] The analysis shows a DT profiles characterized by an endothermic peak with onset at about 198 C. and maximum at 210.6 C.
[0054] This peak, attributable to melting with release of crystallisation solvent, is associated to a weight loss of 5.34% from 195 C. to 230 C.
[0055] The TG profile shows also a progressive weight loss of about 6.7% from 30 to 195 C.
[0056] The total loss of weight from 30 C. to 230 C. is 12.1%.
[0057] The XRPD diffractogram of IDN5404 (EtOH solvate) is represented in
[0058] The diffractogram is characterized by intense diffraction peaks and sharp peak profile which indicates high crystallinity; the XRPD pattern shows distinctive reflections, expressed as 2-theta degrees values, at: 6.3-10.4-10.6-11.2-12.5-13.3-14.4-14.8-16.9-17.8-18.8-19.3-19.7-20.3-20.9-21.8-22.5-23.0-23.3-24.9-25.5-26.0-27.1-27.9-28.9-29.4-29.7-32.2.
[0059] Stability Data
[0060] The amorphous form of compound (I) has been found to be chemically stable at 252 C./605% relative humidity for at least three years and at 402 C./755% relative humidity for at least 6 moths, as none impurity has departed from its initial To value. The analyses were performed by HPLC.
[0061] The amorphous form of compound (I) has also been found physically stable at 252 C./605% relative humidity for at least three years and at 402 C./755 relative humidity for at least 6 months, as it maintained the characteristics features reported in
[0062] The crystalline IDN 5404 obtained in Example 2 shows a variation in the chemical composition of 7% after one month at 402 C./755% relative humidity.
[0063] The crystalline IDN 5404 obtained in Example 3 shows a variation in the chemical composition of 4.1% after one month at 402 C./755% relative humidity.